Advertisement

A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent

Published:April 08, 2016DOI:https://doi.org/10.1016/j.ejso.2016.03.016

      Abstract

      Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication.
      In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed.
      Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Sugarbaker P.H.
        Building on a consensus.
        J Surg Oncol. 2008; 98: 215-216
        • Kusamura S.
        • Baratti D.
        • Younan R.
        • Deraco M.
        The Delphi approach to attain consensus in methodology of locao regional therapy for peritoneal surface malignancy.
        J Surg Oncol. 2008; 98: 217-219
        • Hultman B.
        • Lind P.
        • Glimelius B.
        • et al.
        Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy.
        Acta Oncol. 2013; 52 ([Epub 2012 Sep. 14]): 824-830https://doi.org/10.3109/0284186X.2012.702925
        • Glehen O.
        • Schreiber V.
        • Cotte E.
        • et al.
        Cytoreductive surgery and intraperitoneal chemohyerthermia for peritoneal carcinomatosis arising from gastric cancer.
        Arch Surg. 2004; 139: 20-26
        • Gehen O.
        • Gilly F.N.
        • Arvieux C.
        • et al.
        Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy.
        Ann Surg Oncol. 2010; 17: 2370-2377https://doi.org/10.1245/s10434-010-1039-7
        • Yu W.S.
        • Sugarbaker P.H.
        Early postoperative intraperitoneal chemotherapy for gastric cancer.
        Cancer Treat Res. 1991; 55: 265-275
        • Yonemura Y.
        • Endou Y.
        • Bando E.
        • et al.
        The usefulness of oral TS-1 treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells.
        Cancer Ther. 2006; 4: 135-142
        • Yonemura Y.
        • Canbay E.
        • Sako S.
        • et al.
        Phase II study of a comprehensive treatment using perioperative chemotherapy combined with cytoreductive surgery for curatively resected gastric cancer patients with positive peritoneal wash cytology.
        Glob J Gastroenterol Hepatol. 2014; 2: 108-113
        • Yonemura Y.
        • Canbay E.
        • Endou Y.
        • et al.
        Peritoneal cancer treatment.
        Expert Opin. 2014; 15: 623-636https://doi.org/10.1517/14656566.2014.879571
        • Verwaal V.J.
        • Bruin A.
        • Boot H.
        • van Slooten G.
        • van Tinteren H.
        8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
        Ann Surg Oncol. 2008; 15: 2633-2635https://doi.org/10.1245/s10434-008-0108-7
        • O'Dwyer S.
        • Verwaal V.J.
        • Sugarbaker P.H.
        Evolution of treatment for peritoneal metastasis from colorectal cancer.
        J Clin Oncol. 2015; 33https://doi.org/10.1200/JCO.2015.61.3902
        • National Institute for Health and Clinical Excellence (NICE)
        Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
        February 2010 (IPG 331) ([accessed 13.08.13])
        • Valle M.
        • Federici O.
        • Garofalo A.
        Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging and treatment.
        Surg Oncol Clin N Am. 2012; : 515-531
        • Jacquet P.
        • Sugarbaker P.H.
        Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
        Cancer Treat Res. 1996; 82: 359-374
        • Koh J.L.
        • Yan T.D.
        • Glenn D.
        • Morris D.L.
        Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis.
        Ann Surg Oncol. 2009; 16: 327-333https://doi.org/10.1245/s10434-008-0234-2
        • Kuramoto M.
        • Shimada S.
        • Ikeshima S.
        • et al.
        Etensive intraperitoneal peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric cancer.
        Ann Surg. 2009; 250: 242-246https://doi.org/10.1097/SLA.0b013e3181b0c80e
        • Yonemura Y.
        • Canbay E.
        • Sako S.
        • et al.
        management of peritoneal metastases developed from gastric cancer: laparascopic hyperthermic intraperitoneal chemontherapy in neoadjuvant setting.
        Integr Oncol. 2014; 3: 1https://doi.org/10.4172/2339-6771.1000117
        • Yonemura Y.
        • Endou Y.
        • Shinbo M.
        • et al.
        Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery.
        J Surg Oncol. 2009; 15: 311-316https://doi.org/10.1002/jso.21324
        • Yonemura Y.
        • Bandou E.
        • Sawa T.
        • et al.
        A new treatment by neoadjuvant intraperitoneal-systemic chemotherapy and peritonectomy for peritoneal dissemination from gastric cancer.
        Eur J Surg Oncol. 2006; 32: 661-665
        • Yonemura Y.
        • Canbay E.
        • Endou Y.
        • et al.
        A new bidirectional intraperitoneal and systemic induction chemotherapy (BISIC) for the peritoneal metastasis from gastric cancer in neoadjuvant setting.
        Integr Cancer Sci Ther Integr Cancer Sci Ther. 2014; 1: 26-29https://doi.org/10.15761/ICST.1000106
        • Yu W.
        • Whang I.
        • Averbach A.
        • Chang D.
        • Sugarbaker P.H.
        Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer.
        Am Surg. 1998; 64: 1104-1108
        • Kurimoto K.
        • Ishigure K.
        • Mochizuki Y.
        • et al.
        A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106).
        Gastric Cancer. 2015; 18 ([Epub 2014 May 18]): 354-359https://doi.org/10.1007/s10120-014-0384-9
        • Japanese Research Society for Gastric Cancer
        The general rules for gastric cancer study.
        Kanahara Shuppan, Tokyo1995
        • Bando E.
        • Yonemura Y.
        • Takeshita Y.
        • et al.
        Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma.
        Am J Surg. 1999; 178: 256-262
        • Sobin L.H.
        • Gospodarowicz M.K.
        • Witterkind C.
        International Union against cancer (UICC) TNM classification of malignant tumor.
        7th ed. Wiley-Liss, New York2010
        • Yang X.J.
        • Li Y.
        • Yonemura Y.
        Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center.
        J Surg Oncol. 2010; 101: 457-464
        • Coccolini F.
        • Catena F.
        • Glehen O.
        • et al.
        Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cutoff. Systemic review and meta-analysis.
        Eur J Surg Oncol. 2015; 41: 911-919https://doi.org/10.1016/j.ejso.2015.03.231
        • Yonemura Y.
        • Elnemr A.
        • Endou Y.
        • et al.
        Multidisciplinary therapy for treatment of peritoneal carcinomatosis from gastric cancer.
        World J Gastrointest Oncol. 2010; 15: 85-97https://doi.org/10.4251/wjgo.v2.i2.85
        • Yan T.D.
        • Black D.
        • Sugarbaker P.H.
        • et al.
        A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.
        Ann Surg Oncol. 2007; 14: 2702-2713https://doi.org/10.1245/s10434-007-9487-4
        • Pôfannenberg C.
        • Knigstainer
        • Aschoff P.
        • et al.
        (18)F-FDG-PET-CTto select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
        Ann Surg Oncol. 2009; 16: 1295-1303
        • Hong S.H.
        • Shin Y.R.
        • Roh Y.
        • et al.
        Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center.
        Gastric Cancer. 2013; 16: 290-300https://doi.org/10.1007/s10120-012-0182-1
        • Valle M.
        • Garofalo A.
        Laparoscopic staging of peritoneal surface malignancies.
        Eur J Surg Oncol. 2006; 32: 625-627
        • Thomas F.
        • Ferron G.
        • Gesson-Paute A.
        • Hristova M.
        • Lochon I.
        • Chatelut E.
        Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy.
        Ann Surg Oncol. 2008; 15: 3623-3624https://doi.org/10.1245/s10434-008-0115-8
        • Baron M.A.
        Structure of intestinal peritoneum in man.
        Am J Anat. 1941; 69: 439-497
        • Los G.
        • Mutsaers P.H.A.
        • van der Vijgh W.J.
        • Baldew G.S.
        • de Graaf P.W.
        • McVie J.G.
        Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy.
        Cancer Res. 1989; 49: 3380-3384
        • de Bree E.
        • Tsiftsis D.D.
        Experimental and pharmacologic studies in intraperitoneal chemotherapy from laboratory bench to bedside. Advances in peritoneal surface oncology.
        in: Gonzalez-Moleno S. Springer, 2007: 53-73
        • Ishigami H.
        • Kitayama J.
        • Kaisaki S.
        • et al.
        Phase II study of weekly intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for advanced gastric cancer with peritoneal metastasis.
        Ann Oncol. 2010; 21: 67-70https://doi.org/10.1093/annonc/mdp260
        • Coccolini F.
        • Cotte E.
        • Glehen O.
        • et al.
        Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials.
        Eur J Surg Oncol. 2013; https://doi.org/10.1016/j.ejso.2013.10.019
        • Mizumoto A.
        • Canbay E.
        • Hirano M.
        • et al.
        Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan.
        Gastroenterol Res Pract. 2012; 2012 (5 pp): 1-5836425https://doi.org/10.1155/2012/836425
        • Glehen O.
        • Gilly F.N.
        • Cotte E.
        Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism?.
        Ann Surg Oncol. 2011; 18: 1524-1526https://doi.org/10.1245/s10434-011-1632-4
        • Yonemura Y.
        • Elnemr A.
        • Endou Y.
        • et al.
        Surgical results of patients with peritoneal carcinomatosis treated with cytoreductive surgery using a new technique named aqua dissection.
        Gastroenterol Res Pract. 2012; 2012: 10521487https://doi.org/10.1155/2012/521487
        • Yang X.J.
        • Huang C.Q.
        • Suo T.
        • et al.
        Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
        Ann Surg Oncol. 2011; 18 ([Epub 2011 Mar 23]): 1575-1581https://doi.org/10.1245/s10434-011-1631-5
        • Levine E.A.
        • Stewart J.H.
        • Russel G.B.
        • et al.
        Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures.
        J Am Coll Surg. 2007 May; 204: 943-953https://doi.org/10.1016/j.jamollsurg.2006.12.048
        • Hall J.J.
        • Loggie B.W.
        • Shen P.
        • et al.
        Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer.
        J Gastrointest Surg. 2004; 8: 454-463
        • Magge D.
        • Zenati M.
        • Mavanur A.
        • et al.
        Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.
        Ann Surg Oncol. 2014; 21: 1448-1455
        • Yonemura Y.
        • Kawamura T.
        • Bandou E.
        • Takahashi S.
        • Sawa T.
        • Matsuki N.
        Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion.
        Br J Surg. 2005; 92: 370-375
        • Canbay E.
        • Yonemura Y.
        Peritoneal metastases of gastric cancer, peritoneal surface malignancy. A curative approach.
        in: Canbay E. Yonemura Y. Springer, Cham, Heidelberg, New York, Dordrecht, London2015: 69-70https://doi.org/10.1007/978-3-319-12937-2